ENTITY
Samsung Biologics

Samsung Biologics (207940 KS)

438
Analysis
Health Care • South Korea
Samsung Biologics Co.,Ltd. manufactures bio-healthcare products. The Company develops, refines, and distributes biopharmaceutical products.
more
bullish•Samsung Biologics
•11 Nov 2016 06:05

Recap of Samsung BioLogics' First Trading Day - Foreign Institutions Net Purchased 1M Shares

Samsung BioLogics closed at ₩144,000 with 6.67% gain on its first trading day. It started with a relatively weak sentiment at the opening price of...

Logo
320 Views
Share
bullish•Samsung Biologics
•10 Nov 2016 06:20

Samsung BioLogics' First Trading Day - Blunders in Barron's Argument & Price Prediction

As reported by Barron's on Nov 5 ("Samsung BioLogics IPO: Too Expensive"), there are still some skeptical views on BioLogics' IPO valuation....

Logo
404 Views
Share
bearish•Celltrion Inc
•04 Nov 2016 02:56

One World, Two Stories

Celltrion's management continues to make very optimistic projections about Remsima's US sales in 2017 despite regulatory hurdles that will limit...

Share
bullish•SillaJen Inc
•03 Nov 2016 11:26

SillaJen IPO Part 2 - Growth Potential & Appropriate Valuation Level

* In Part 2 (as below), I summarized the growth potential and appropriate valuation level of SillaJen.Apparently, not many people are doubtful...

Logo
342 Views
Share
bullish•Samsung Biologics
•01 Nov 2016 18:11

Samsung BioLogics IPO - Why Investors Are Excited & Concerned

Samsung BioLogics will have a big day tomorrow. Nov 2-3 will be the subscription day. The company has already had a huge success with the...

Logo
429 Views
Share
x